Open Access
Issue
EPJ Nonlinear Biomed Phys
Volume 2, Number 1, December 2014
Article Number 13
Number of page(s) 40
DOI https://doi.org/10.1140/epjnbp/s40366-014-0013-x
Published online 05 November 2014
  1. World Health Organization: WHO global report: Noncommunicable diseases country profiles 2011. Date: September, 2011 ISBN: 9789241502283 [http://www.who.int/nmh/publications/ncd_profiles2011/en/]
  2. KEGG PATHWAY Database - Metabolism[http://www.genome.jp/kegg/pathway.html\#metabolism]
  3. KEGG PATHWAY Database - Cellular Processes[http://www.genome.jp/kegg/pathway.html\#cellular]
  4. KEGG PATHWAY Database - Human Diseases[http://www.genome.jp/kegg/pathway.html\#disease]
  5. Rowinsky EK, Wright M, Monsarrat B, Lesser GJ, Donehower RC: Taxol: pharmacology, metabolism and clinical implications. Cancer Surv1993, 17:283–304.
  6. Huizing MT, Misser VH, Pieters RC, ten Bokkel Huinink WW, Veenhof CH, Vermorken JB, Pinedo HM, Beijnen JH: Taxanes: a new class of antitumor agents. Cancer Invest1995, 13:381–404.
  7. Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, Kim NK, Bang YJ: Phase i and pharmacokinetic study of genexol-pm, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res2004, 10:3708.
  8. Robinson DM, Keating GM: Albumin-bound paclitaxel in metastatic breast cancer drugs. Drugs2006, 66:941.
  9. Mori T, Kinoshita Y, Watanabe A, Yamaguchi T, Hosokawa K, Honjo K: Retention of paclitaxel in cancer cells for 1 week in vivo and in vitro. Cancer Chemother Pharmacol2006, 58:665–675.
  10. Henningsson A, Karlsson MO, Vigano L, Gianni L, Verweij J, Sparreboom AA: Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol2001, 19:4065.
  11. Brana MF, Cacho M, Gradillas A, Pascual-Teresa B, Ramos A: Intercalators as anticancer drugs. Curr Pharm Des2001, 7:1745–1780.
  12. Hickman JA, Beere HM, Wood AC, Waters CM, Parmar R: Mechanisms of cytotoxicity caused by antitumor drugs, 6th international congress of toxicology: toxicology from discovery and experimentation to the human perspective. Toxicol Lett1992, 64–65:553–561.
  13. Kiechle FL, Zhang XB: Apoptosis: biochemical aspects and clinical implications. Clinica Chimica Acta2002, 326:27–45.
  14. Carter SK, Comis RL: Integration of chemotherapy into a combined modality approach for cancer treatment for pancreatic adenocarcinoma. Cancer Treat Rev1975, 2:193–214.
  15. Lenaz L, Page JA: Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat Rev1975, 3:111–120.
  16. Locker GY, Doroshow JH, Myers CE: Glutathione peroxidase - its role in adriamycin cardiotoxicity. In Proceedings of the American Association for Cancer Research: Volume 18. Philadelphia: American Association for Cancer Research; 1977:87.
  17. Wallace KB: Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol Toxicol2003, 93:105–115.
  18. Kurabayashi M, Jeyaseelan R, Kedes L: Doxorubicin represses the function of the myogenic helix-loop-helix transcription factor myod - involvement of id gene induction. J Biol Chem1994, 269:6031–6039.
  19. Boucek RJ, Miracle A, Anderson M, Engelman R, Atkinson J, Dodd DA: Persistent effects of doxorubicin on cardiac gene expression. J Mol Cell Cardiol1999, 31:1435–1446.
  20. Gibaldi M, Perrier D: Pharmacokinetics. 2nd edition, New York: M. Dekker; 1982.
  21. Macheras P: A fractal approach to heterogeneous drug distribution: calcium pharmacokinetics. Pharm Res1996, 13:663–670.
  22. Fuite J, Marsh RE, Tuszynski JA: Fractal pharmacokinetics of the drug mibefradil in the liver. Phys Rev E2002, 66:021904.
  23. Marsh RE, Tuszynski JA, Sawyer MB, Vos KJE: Emergence of power laws in the pharmacokientics of paclitaxel due to competing saturable processes. J Pharmacy Pharmaceutical Sci2008, 11:77–96.
  24. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C: Comparison of multiple amber force fields and development of improved protein backbone parameters. Proteins2006, 65:712–25.
  25. Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, Johnson EF: The structure of human microsomal cytochrome p450 3a4 determined by x-ray crystallography to 2.05-a resolution. J Biol Chem2004, 279:38091–38094.
  26. Bennet MJ, Barakat K, Huzil JT, Tuszynski JA, Schriemer DC: Discovery and characterization of the laulimalide-microtubule binding mode by mass shift perturbation mapping. Chem Biol2010, 17:725–734.
  27. Gianni L, Vigano L, Locatelli A, Capri G, Giani A, Tarenzi E, Bonadonna G: Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol1997, 15:1906–1915.
  28. Moreira A, Lobato R, Morais J, Silva S, Ribeiro J, Figueira A, Vale D, Sousa C, Araujo F, Fernandes A, Oliveira J, Passos-Coelho JL: Influence of the interval between the administration of doxorubicin and paclitaxel on the pharmacokinetics of these drugs in patients with locally advanced breast cancer. Cancer Chemotherapy Pharmacol2001, 48:333–337.
  29. Benjamin RS, Riggs CE, Bachur NR: Influence of the interval between the administration of doxorubicin and paclitaxel on the pharmacokinetics of these drugs in patients with locally advanced breast cancer. Cancer Chemotherapy Pharmacol2001, 48:333–337.
  30. Andersen A, Holte H, Slordal L: Pharmacokinetics and metabolism of doxorubicin after short-term infusions in lymphoma patients. Cancer Chemotherapy Pharmacol1999, 44:422–426.
  31. Greene RF, Collins JM, Jenkins JF, Speyer JL, Myers CE: Plasma pharmacokinetics of adriamycin and adriamycinol: Implications for the design of in vitro experiments and treatment protocols. Cancer Res1983, 43:3417–3421.
  32. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Locatelli A, Bonadonna G, Egorin MJ: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol1995, 13:180–190.
  33. Ohtsu T, Sasaki Y, Tamura T, Miyata Y, Nakanomyo H, Nishiwaki Y, Saijo N: Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res1995, 1:599–606.
  34. Ekroos M, Sjogren T: Structural basis for ligand promiscuity in cytochrome p450 3a4. Proc Natl Acad Sci U S A2006, 103:13682–13687.
  35. Boucek RJ, Olson RD, Brenner DE, Ogunbunmi EM, Inui M, Fleischer S: The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps: A correlative study of cardiac muscle with isolated membrane fractions. J Biol Chem1987, 262:15851–15856.
  36. Hornberg JJ, Bruggeman FJ, Westerhoff HV, Lankelma J: Cancer: a systems biology disease. Biosystems2006, 83:81–90.
  37. Mross K, Niemann B, Massing U, Drevs J, Unger C, Bhamra R, Swenson C: Pharmacokinetics of liposomal doxorubicin (tlc-d99; myocet) in patients with solid tumors: an open-label, single-dose study. Cancer Chemother Pharmacol2004, 54:514–524.
  38. Di Fronzo G, Lenaz L, Bonadonna G: Distribution and excretion of adriamycin in man. Biomedicine1973, 19:169–171.
  39. Jacquet JM, Bressolle F, Galtier M, Bourrier M, Donadio D, Jourdan J, Rossi JF: Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters. Cancer Chemother Pharmacol1990, 27:219–225.
  40. Bressolle F, Ray P, Jacquet JM, Bres J, Galitier M, Donadio D, Jourdan J, Rossi JF: Bayesian estimation of doxorubicin pharmacokinetic parameters. Cancer Chemother Pharmacol1991, 29:53–60.
  41. Eksborg S, Strandler HS, Edsmyr F, Naslund I, Tahvanainen P: Pharmacokinetic study of iv infusions of adriamycin. Eur J Pharmacol1985, 28:205–212.
  42. Chan KK, Chlebowski RT, Tong M, Chen HSG, Gross JF, Bateman JR: Clinical pharmacokinetics of adriamycin in hepatoma patients with cirrhosis. Cancer Res1980, 40:1263–1268.
  43. Monsarrat B, Chatelut E, Royer I, Alvineirie P, Dubois J, Dezeuse A, Roche H, Cros S, Wright M, Canal P: Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome p450 3a4. Drug Metab Dispos1998, 26:229–233.
  44. Mross K, Hollander N, Hauns B, Schumacher M, Maier-Lenz H: The pharmacokinetics of a 1-h paclitaxel infusion. Cancer Chemother Pharmacol2000, 45:463–470.
  45. Brown T, Havlin K, Weiss G, Cagnola J, Koeller J, Kuhn J, Rizzo J, Craig J, Phillips J, Von Hoff D: A phase 1 trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol1991, 9:1261–1267.
  46. Longnecker SM, Donehower RC, Cates AE, Chen TL, Brundrett RB, Grochow LB, Ettinger DS, Colvin M: High-performance liquid chromatography assay for taxol in human plasma and urine and pharmacokinetics in a phase i trial. Cancer Treat Rep1987, 71:53–59.
  47. Gelmon K, Eisenhauer E, Bryce C, Tolcher A, Mayer L, Tomlinson E, Zee B, Blackstein M, Tomiak E, Yau J, Batist G, Fisher B, Iglesias J: Randomized phase ii study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol1999, 17:3038–3047.
  48. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E: Phase I clinical and pharmacokinetic study of taxol. Cancer Res1987, 47:2486–2493.
  49. Maier-Lenz H, Hauns B, Haering B, Koetting J, Mross K, Unger C, Bauknecht T, duBois A, Meerpohl HG, Hollaender N, Diergarten K: Phase i study of paclitaxel administration as a 1-hr infusion: Toxicity and pharmacokinetics. Semin Oncol1997, 24:19–161919.

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.